Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in ReceivablesChange in Working CapitalDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Addex Therapeutics (ADXN) Depreciation & Amortization (CF) (2022 - 2025)

Historic Depreciation & Amortization (CF) for Addex Therapeutics (ADXN) over the last 4 years, with Q2 2025 value amounting to -$2.6 billion.

  • Addex Therapeutics' Depreciation & Amortization (CF) rose 9671.18% to -$2.6 billion in Q2 2025 from the same period last year, while for Sep 2025 it was -$270.0 billion, marking a year-over-year decrease of 144014.03%. This contributed to the annual value of $295678.8 for FY2024, which is 1320.42% down from last year.
  • According to the latest figures from Q2 2025, Addex Therapeutics' Depreciation & Amortization (CF) is -$2.6 billion, which was up 9671.18% from $2.4 billion recorded in Q1 2025.
  • Addex Therapeutics' 5-year Depreciation & Amortization (CF) high stood at $272.8 billion for Q3 2024, and its period low was -$269.8 billion during Q4 2024.
  • For the 4-year period, Addex Therapeutics' Depreciation & Amortization (CF) averaged around $262.1 million, with its median value being $84233.5 (2022).
  • The largest annual percentage gain for Addex Therapeutics' Depreciation & Amortization (CF) in the last 5 years was 19430315172.03% (2023), contrasted with its biggest fall of 32527658758.1% (2023).
  • Over the past 4 years, Addex Therapeutics' Depreciation & Amortization (CF) (Quarter) stood at $78524.3 in 2022, then plummeted by 325276587.58% to -$255.4 billion in 2023, then dropped by 5.61% to -$269.8 billion in 2024, then skyrocketed by 99.05% to -$2.6 billion in 2025.
  • Its Depreciation & Amortization (CF) was -$2.6 billion in Q2 2025, compared to $2.4 billion in Q1 2025 and -$269.8 billion in Q4 2024.